These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20674358)

  • 1. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents.
    Li B; Jones ED; Zhou E; Chen L; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5334-6. PubMed ID: 20674358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents.
    Ben L; Jones ED; Zhou E; Li C; Baylis DC; Yu S; Wang M; He X; Coates JA; Rhodes DI; Pei G; Deadman JJ; Xie X; Ma D
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4012-4. PubMed ID: 20561788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S; Nishikawa Y; Ichikawa T; Hattori T; Matsushita Y; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
    Bioorg Med Chem; 2005 Jan; 13(2):397-416. PubMed ID: 15598561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
    Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
    J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.
    Kim D; Wang L; Hale JJ; Lynch CL; Budhu RJ; Maccoss M; Mills SG; Malkowitz L; Gould SL; DeMartino JA; Springer MS; Hazuda D; Miller M; Kessler J; Hrin RC; Carver G; Carella A; Henry K; Lineberger J; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2129-34. PubMed ID: 15808483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of tropane-derived CCR5 receptor antagonists.
    Armour DR; de Groot MJ; Price DA; Stammen BL; Wood A; Perros M; Burt C
    Chem Biol Drug Des; 2006 Apr; 67(4):305-8. PubMed ID: 16629828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
    Duan M; Aquino C; Ferris R; Kazmierski WM; Kenakin T; Koble C; Wheelan P; Watson C; Youngman M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1610-3. PubMed ID: 19233649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.
    Zhang HS; Feng DZ; Chen L; Long YQ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2219-23. PubMed ID: 20207141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N'-diphenylureas.
    Imamura S; Kurasawa O; Nara Y; Ichikawa T; Nishikawa Y; Iida T; Hashiguchi S; Kanzaki N; Iizawa Y; Baba M; Sugihara Y
    Bioorg Med Chem; 2004 May; 12(9):2295-306. PubMed ID: 15080927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.
    Barber CG; Blakemore DC; Chiva JY; Eastwood RL; Middleton DS; Paradowski KA
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1075-9. PubMed ID: 19171484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
    Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
    Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.
    Shen DM; Shu M; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):935-9. PubMed ID: 15012997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent.
    Ma D; Yu S; Li B; Chen L; Chen R; Yu K; Zhang L; Chen Z; Zhong D; Gong Z; Wang R; Jiang H; Pei G
    ChemMedChem; 2007 Feb; 2(2):187-93. PubMed ID: 17163560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives.
    Wei RG; Arnaiz DO; Chou YL; Davey D; Dunning L; Lee W; Lu SF; Onuffer J; Ye B; Phillips G
    Bioorg Med Chem Lett; 2007 Jan; 17(1):231-4. PubMed ID: 17081751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.
    Ernst J; Dahl R; Lum C; Sebo L; Urban J; Miller SG; Lundström J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1498-501. PubMed ID: 18194864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor.
    Shankaran K; Donnelly KL; Shah SK; Guthikonda RN; MacCoss M; Mills SG; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Carella A; Carver G; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3419-24. PubMed ID: 15177445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.
    Hale JJ; Budhu RJ; Holson EB; Finke PE; Oates B; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano S; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini E
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2741-5. PubMed ID: 11591514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of CCR5 receptor antagonists for the treatment of HIV infection: hit-to-lead studies.
    Armour D; de Groot MJ; Edwards M; Perros M; Price DA; Stammen BL; Wood A
    ChemMedChem; 2006 Jul; 1(7):706-9. PubMed ID: 16902922
    [No Abstract]   [Full Text] [Related]  

  • 19. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
    J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists.
    Shankaran K; Donnelly KL; Shah SK; Caldwell CG; Chen P; Finke PE; Oates B; MacCoss M; Mills SG; DeMartino JA; Gould SL; Malkowitz L; Siciliano SJ; Springer MS; Kwei G; Carella A; Carver G; Danzeisen R; Hazuda D; Holmes K; Kessler J; Lineberger J; Miller MD; Emini EA; Schleif WA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3589-93. PubMed ID: 15177481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.